Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
182.1 USD | +0.97% | +2.59% | +17.51% |
Mar. 27 | Barclays Raises AbbVie Price Target to $195 From $185, Maintains Overweight Rating | MT |
Mar. 25 | Deals of the day-Mergers and acquisitions | RE |
Financials (USD)
Sales 2024 * | 54.54B | Sales 2025 * | 57.81B | Capitalization | 322B |
---|---|---|---|---|---|
Net income 2024 * | 9.36B | Net income 2025 * | 11.12B | EV / Sales 2024 * | 6.84 x |
Net Debt 2024 * | 50.81B | Net Debt 2025 * | 42.29B | EV / Sales 2025 * | 6.31 x |
P/E ratio 2024 * |
33.9
x | P/E ratio 2025 * |
27.5
x | Employees | 50,000 |
Yield 2024 * |
3.42% | Yield 2025 * |
3.57% | Free-Float | 96.74% |
Latest transcript on AbbVie Inc.
1 day | +0.97% | ||
1 week | +2.59% | ||
Current month | +3.44% | ||
1 month | +2.30% | ||
3 months | +17.67% | ||
6 months | +19.61% | ||
Current year | +17.51% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Gonzalez
CEO | Chief Executive Officer | 70 | 12-12-31 |
Scott Reents
DFI | Director of Finance/CFO | 57 | 12-12-31 |
Robert Michael
PSD | President | 53 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 63 | 12-12-31 |
Edward Rapp
BRD | Director/Board Member | 66 | 12-12-31 |
Director/Board Member | 70 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
7.12% | 6 M€ | +6.10% | - | |
6.85% | 18 M€ | +6.77% | - | |
6.26% | 13 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 182.1 | +0.97% | 5,418,687 |
24-03-27 | 180.4 | +0.65% | 5,073,508 |
24-03-26 | 179.2 | +0.37% | 4,392,427 |
24-03-25 | 178.5 | +0.04% | 4,366,502 |
24-03-22 | 178.4 | +0.54% | 4,084,352 |
Delayed Quote Nyse, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.51% | 322B | |
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+0.74% | 209B | |
+2.95% | 212B | |
-6.05% | 205B | |
-3.61% | 157B | |
-1.28% | 152B |